IFF announced the sale of its Food Ingredients unit to funds advised by CVC Capital Partners for about $4.3 billion, with IFF retaining roughly 10% and a board seat. The move focuses resources on Taste, Scent, and Health & Biosciences, improving cash flow and financial flexibility while guiding long-term growth; closing is targeted by late Q2 2027. Near term, EPS may be diluted, but deleveraging and value creation are anticipated over time.
Significant cash proceeds enable deleveraging and potential buybacks; focus on higher-growth segments may lead to multiple expansion over time, despite near-term EPS dilution.
Medium term upside from deleveraging and higher-margin growth, offset by near-term EPS dilution; watch 2Q2027 close and 2026 guidance realization over 12–24 months.
M&A-driven corporate portfolio optimization. The transaction reshapes IFF into a leaner, higher-growth platform, aligning with its strategy to emphasize core, higher-margin businesses.